Business ❯ Pharmaceuticals

Biotechnology

Drug Development Mergers and Acquisitions Acquisitions Cancer Treatment Contract Research Organizations Moderna Biosimilars Research and Development Vaccine Development mRNA Technology RNA Medicines Clinical Trials Active Ingredients Amylyx Pharmaceuticals, Inc. Biopharmaceutical Companies Market Trends Clinical Research Contract Manufacturing Artificial Intelligence Collaboration Healthcare Partnerships Fermentation Technology Partnerships Clinical Development Vaccine Production Gene Editing RNA Therapeutics Cell Therapy Drug Discovery Cancer Therapies AI Collaboration Obesity Drugs Capacity Building Public Companies Prevacus BioNTech Regulatory Approval Market Impact Emerging Companies Diagnostics Royalty Agreements Medical Products Logistics Gene Therapy

Metsera Backs Pfizer’s $10 Billion Deal, Citing Regulatory Risks in Novo Bid

FTC concerns over Novo’s two-step structure made Pfizer’s revised offer the board’s preferred path.

Vertex Tops Q3 Estimates on CF Franchise as New Drugs Miss and Outlook Edges Higher

Biogen Licenses Vanqua’s Preclinical C5aR1 Drug in Deal Worth Up to $1.06 Billion

Takeda Strikes $11 Billion-Plus Oncology Deal With Innovent, Pays $1.2 Billion Upfront

Rani Therapeutics and Chugai Sign Oral Biologics Collaboration Worth Up to $1.085 Billion

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

Takeda and Nabla Bio Expand AI Protein-Design Deal With Potential Payouts Above $1 Billion

Bristol Myers Squibb Buys Orbital Therapeutics for $1.5 Billion to Push In Vivo CAR‑T Into Autoimmune Care